T9G — Vidac Pharma Holding Income Statement
0.000.00%
Last trade - 00:00- €18.70m
- €18.67m
Annual income statement for Vidac Pharma Holding, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | |
|---|---|---|
| Period Length: | 5 M | 12 M |
| Source: | ARS | ARS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 0 | 0 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Depreciation and Amortization | ||
| Total Operating Expenses | 0.407 | 0.609 |
| Operating Profit | -0.407 | -0.609 |
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -0.406 | -0.643 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -0.406 | -0.643 |
| Net Income Before Extraordinary Items | ||
| Net Income | -0.406 | -0.643 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Dilution Adjustment | ||
| Diluted Net Income | -0.406 | -0.643 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -0.008 | -0.012 |
| Dividends per Share |